Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.

BMC medicine - 21 Jul 2021

Long Junyu, Wang Dongxu, Yang Xu, Wang Anqiang, Lin Yu, Zheng Mingjun, Zhang Haohai, Sang Xinting, Wang Hanping, Hu Ke, Zhao Haitao

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently mutated in several cancer types, but its role in immunotherapy is still unclear. Our study is the first to study the association between NOTCH4 mutation and the response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Receptor, Notch4

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34284787
DOI: 10.1186/s12916-021-02031-3
PMCID: PMC8293505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.PMID 34284787Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal CancerSemantic proximity Read ↗

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.